Patents by Inventor Cahil McGovern

Cahil McGovern has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS
    Publication number: 20220071897
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Application
    Filed: November 18, 2021
    Publication date: March 10, 2022
    Inventors: Jeffrey Louis GOLDBERG, Cahil MCGOVERN, Weng TAO, Konrad A. KAUPER
  • Use of encapsulated cell therapy for treatment of ophthalmic disorders
    Patent number: 11207266
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 28, 2021
    Assignee: Neurotech, USA, Inc.
    Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad A. Kauper
  • USE OF ENCAPSULATED CELL THERAPY FOR TREATMENT OF OPHTHALMIC DISORDERS
    Publication number: 20200197297
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Application
    Filed: September 6, 2019
    Publication date: June 25, 2020
    Inventors: Jeffrey Louis GOLDBERG, Cahil MCGOVERN, Weng TAO, Konrad A. KAUPER
  • Use of encapsulated cell therapy for treatment of ophthalmic disorders
    Patent number: 10456356
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 29, 2019
    Assignee: Neurotech USA, Inc.
    Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad Kauper
  • Use of encapsulated cell therapy for treatment of ophthalmic disorders
    Patent number: 10195140
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 5, 2019
    Assignee: Neurotech USA, Inc.
    Inventors: Cahil McGovern, Weng Tao, Konrad Kauper
  • Use of Encapsulated Cell Therapy for Treatment of Ophthalmic Disorders
    Publication number: 20180055766
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 1, 2018
    Inventors: Cahil McGovern, Weng Tao, Konrad Kauper
  • Use of Encapsulated Cell Therapy for Treatment of Ophthalmic Disorders
    Publication number: 20160346197
    Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad Kauper